M&A
Cohance invests $13-M more in US-based NJ Bio; hikes stake to 67.3%
BSE Announcement Business Line
Hyderabad-based Cohance Lifesciences (formerly known as Suven Pharmaceuticals) has invested USD 13-M more in Princeton, NJ (USA)-based NJ Bio , which increases the firm's common-equity ownership in the company from 56% to 67.3%.NJ Bio is a contract research and manufacturing organisation specialising in antibody-drug conjugates.
In Dec 2024, Suven Pharmaceuticals acquired a 56% controlling stake in Princeton,NJ -based NJ Bio Inc for USD 64 million.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
